FDA Adverse Event Injury Summary report: N

XIENCE PRIME LL EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 4232932 · Received November 6, 2014

Report

Report Number
2024168-2014-07267
Event Type
Injury
Date Received
November 6, 2014
Date of Event
July 7, 2014
Report Date
October 15, 2014
Manufacturer
AV-TEMECULA-CT
Product Code
NIQ
PMA / PMN Number
P110019
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IN
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4). DURING PROCESSING OF THIS COMPLAINT, ATTEMPTS WERE MADE TO OBTAIN COMPLETE EVENT, PATIENT AND DEVICE INFORMATION. THE DEVICE IS EXPECTED TO BE RETURNED FOR INVESTIGATION. IT HAS NOT YET BEEN RECEIVED. A FOLLOW-UP REPORT WILL BE SUBMITTED WITH ALL ADDITIONAL RELEVANT INFORMATION.

Additional Manufacturer Narrative · 1

(B)(4). CORRECTION - DEVICE WAS NOT RETURNED. THE STENT REMAINS IN THE VESSEL; IT IS INDICATED THAT THE DEVICE IS NOT RETURNING FOR EVALUATION; THEREFORE A FAILURE ANALYSIS OF THE COMPLAINT DEVICE COULD NOT BE COMPLETED. A REVIEW OF THE LOT HISTORY RECORD REVEALED NO NON-CONFORMANCES THAT WOULD HAVE CONTRIBUTED TO THE REPORTED EVENT. BASED ON THE INFORMATION REVIEWED, THERE IS NO EVIDENCE TO INDICATE THE PRESENCE OF A PRODUCT DEFICIENCY.

Description of Event or Problem · 1

IT WAS REPORTED THAT USING A FEMORAL ARTERY ACCESS APPROACH DURING A PROCEDURE OF THE MODERATELY CALCIFIED, MODERATELY TORTUOUS, DE NOVO, DISTAL LEFT ANTERIOR DESCENDING (LAD) ARTERY THE 2.5 X 38 MM XIENCE PRIME STENT WAS DEPLOYED, HOWEVER, A DISTAL EDGE DISSECTION WAS NOTED. A 2.5 X 23 MM XIENCE V STENT WAS USED AS TREATMENT WITHOUT REPORTED ADVERSE PATIENT SEQUELA. THERE WAS NO REPORTED CLINICALLY SIGNIFICANT DELAY IN THE PROCEDURE. NO ADDITIONAL INFORMATION WAS PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
712912 XIENCE PRIME LL EVEROLIMUS ELUTING CORONARY STENT SYSTEM DRUG ELUTING CORONARY STENT SYSTEM NIQ AV-TEMECULA-CT 4010941

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention